ArticleNeuromolecular medicine2025
SP3-Mediated Transcriptional Activation of GRIK1 is Involved in Alzheimer's Disease-Induced Cognitive Decline by Inducing Inflammasome Activation in Microglia.
Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cystathionine β-synthase is inhibited by epinephrine and norepinephrine over-secretion via NF-κB activation in stress-induced hyperhomocysteinemia.Scientific reports · 2026Article
- The APOE4-estrogen-microglia axis in perimenopausal cognitive changes: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
GRIK1 has been identified to suppress the activation of NLRP3 inflammasome. The present study investigated the damaging effect of GRIK1 on Alzheimer's disease (AD), the most common neurodegenerative disease, by focusing on inflammasome. APP-PS1 mice were subjected to a Y-maze test and a Morris water maze test. APP-PS1 mice with GRIK1 knockdown were constructed using adeno-associated virus, and the effects of GRIK1 knockdown on the NLRP3 inflammasome activation in microglia of brain tissues of APP-PS1 mice were analyzed. Mouse primary microglia BV2 was induced by LPS, and Western blot, flow cytometry, and ELISA were performed. GRIK1 was significantly elevated in the brain tissues of APP-PS1 mice. GRIK1 knockdown inhibited the neuronal damage and NLRP3 neuroinflammation in the brain tissues and improved cognitive dysfunction of APP-PS1 mice. Knockdown of GRIK1 inhibited activation of NLRP3 inflammasome in BV2 cells. SP3 was upregulated in the brain tissues of APP-PS1 mice, and SP3 promoted GRIK1 transcription by binding to its promoter. Overexpression of GRIK1 reversed the mitigating effect of knockdown of SP3 on cognitive dysfunction and NLRP3 activation in APP-PS1 mice. Overall, our results revealed that SP3-induced GRIK1 transcription potentiates NLRP3 inflammasome activation in microglia, leading to cognitive dysfunction in AD.
Indexed as
Identifiers
40055261What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.